These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3622304)

  • 21. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclandelate in diabetic radiculoneuropathy.
    van der Drift JH
    Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of cyclandelate on cholesterol metabolism in patients with familial hypercholesterolaemia.
    Gevers Leuven JA; vd Voort H; Kempen HJ; de Wit E; Havekes L
    Drugs; 1987; 33 Suppl 2():131-5. PubMed ID: 3304952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 25. [Controlled clinical study of Novodil in the treatment of senile macular lesions].
    Delafoulhouje C; Dalens H; Solé P
    Bull Soc Ophtalmol Fr; 1985 Oct; 85(10):1065-7. PubMed ID: 3915881
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders.
    Albizzati MG; Bassi S; Sbacchi M; Frattola L
    Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy.
    De Leeuw IH; Van Rooy P; Moeremans M; Driessens M
    Drugs; 1987; 33 Suppl 2():125-30. PubMed ID: 3304951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs.
    Reich T
    J Am Geriatr Soc; 1977 May; 25(5):202-5. PubMed ID: 853204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.
    Sourander L; Blakemore CB
    Angiology; 1978 Feb; 29(2):133-8. PubMed ID: 347985
    [No Abstract]   [Full Text] [Related]  

  • 30. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical value of a combined anti-ischemic and anticholinergic substance with antidepressant properties.
    Brasseur R
    Angiology; 1978 Feb; 29(2):121-32. PubMed ID: 646177
    [No Abstract]   [Full Text] [Related]  

  • 32. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
    Maina G; Fiori L; Torta R; Fagiani MB; Ravizza L; Bonavita E; Ghiazza B; Teruzzi F; Zagnoni PG; Ferrario E
    Neuropsychobiology; 1989; 21(3):141-5. PubMed ID: 2693996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determination of the anti-anoxia capacity of drugs].
    Truchaud M
    Sem Hop Ther; 1977 Nov; 53(9):425-9. PubMed ID: 341317
    [No Abstract]   [Full Text] [Related]  

  • 34. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
    Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
    Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
    Cheon Y; Park J; Joe KH; Kim DJ
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs and dementia.
    Judge TG
    Br J Clin Pharmacol; 1976 Feb; 3(1 Suppl 1):81-2. PubMed ID: 973950
    [No Abstract]   [Full Text] [Related]  

  • 38. [Diagnostic scales of primary degenerative dementia].
    Krzymińska E; Rossa G; Krzymiński S
    Psychiatr Pol; 1991; 25(6):26-7. PubMed ID: 1841394
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycosaminoglycan polysulfate in old-age dementias: a factor-analytic study of change in psychopathologic symptoms.
    Morey LC; Ban TA; Cassano G; Santini V; Placidi GF; Modafferi A; Postiglione A
    Neuropsychobiology; 1988; 19(3):135-8. PubMed ID: 3059221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.